相关实验视频

Updated: Jan 7, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

抑制TIM-3增强了乳腺瘤的进展和转移:一个矛盾的免疫检查点反应

Barnali Dolui¹, Banani Majumdar¹, Arghya Bandyopadhyay²

¹Department of Zoology, The University of Burdwan, Burdwan, India.

The Journal of biological chemistry

|December 24, 2025

概括

阻断T细胞免疫球蛋白和含有-3 (TIM-3) 的乳腺瘤增长和小鼠肝脏转移的矛盾加速. 这项免疫检查点阻塞研究揭示了促进瘤进展的复杂分子变化,挑战了当前的癌症免疫治疗策略.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

含有-3 (TIM-3) 的T细胞免疫球蛋白和粘素域是一种针对癌症免疫治疗的免疫检查点受体.
在瘤进展中TIM-3阻断的确切作用仍然不完全理解.
免疫检查点抑制剂旨在增强抗瘤免疫反应.

研究的目的:

在小鼠乳腺瘤模型中研究TIM-3抑制的分子后果.
评估反TIM-3抗体对瘤生长和转移的影响.
为了阐明TIM-3阻塞引起的信号通路和细胞变化.

主要方法:

使用了一种用抗TIM-3单克隆抗体治疗的小鼠乳腺瘤模型.
采用流细胞测量来分析瘤透免疫细胞 (CD8 +,CD3 +,FOXP3 +).
进行了血清和瘤细胞因子分析,蛋白质组分析和基因组丰富分析 (GSEA).

主要成果:

阻断TIM-3导致瘤生长加速和肝转移的增加.
观察到瘤透的CD8+ T细胞的矛盾增加和CD3+和FOXP3+ T细胞的减少.
确定了PI3K/Akt-mTORC信号的上调,增强了表皮细胞到介质细胞的过渡 (EMT) 和c-MYC信号,以及抑制的自和亡通路.

结论:

矛盾的是,TIM-3抑制可以促进瘤的进展和转移,这与治疗期望相反.
这些发现挑战了免疫检查点封锁的普遍有效性,并突出了取决于背景的效应.
这项研究揭示了新的分子机制,TIM-3阻断可能会增强瘤的攻击性.

关键词:

乳腺癌是什么? 乳腺癌是什么?表皮细胞-介质细胞过渡.免疫疗法免疫疗法肝脏转移的发生.瘤免疫学瘤免疫学

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...